Back

Finerenone-related risk of hypotension in patients with heart failure with mildly reduced or preserved ejection fraction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drugs, devices, and diagnostics in heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Foa'

University Hospital of Bologna S. Orsola-Malpighi Polyclinic, Bologna (Italy)

7 More presentations in this session

Presentation thumbnail
Effects of beta-blockers on exercise capacity and hemodynamic response during CPET with echocardiography in heart failure with preserved ejection fraction
Doctor S. Dhont (Genk, BE) Doctor P. Bertrand (Genk, BE)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on left ventricular-arterial coupling and myocardial extracellular volume in patients with type 2 diabetes mellitus and HFpEF
Doctor A. Marathonitis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Hemodynamic effects of lactate infusion in chronic heart failure patients
Doctor N. Abild Jespersen (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Resynchronization reduces arginase activity in red blood cells of heart failure patients with dyssynchrony
Doctor K. Ljung (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease
Doctor D. Yoshiura (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Drugs, devices, and diagnostics in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
HOT LINE 7
thumbnail
Congress Presentation
Finerenone in patients with heart failure and diabetic kidney disease: comparison of mineralocorticoid receptor antagonists. FINARM study
thumbnail
Congress Presentation
Early experience with finerenone in patients with heart failure and diabetic kidney disease: 6 months of real-world cohort follow-up

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources